$3.80 +0.24 (6.74%)

Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO)

Orchestra BioMed Holdings, Inc. is a medical device company focused on developing and commercializing innovative solutions for cardiovascular and other medical conditions. The company leverages a combination of proprietary technologies and strategic partnerships to bring minimally invasive and durable devices to market. Its portfolio includes products aimed at improving treatment outcomes and patient quality of life.

🚫 Orchestra BioMed Holdings, Inc. Ordinary Shares does not pay dividends

Company News

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
GlobeNewswire Inc. • Orchestra Biomed • September 4, 2025

Orchestra BioMed presented clinical data showing AVIM therapy can sustainably reduce blood pressure in patients, with effects that are reversible and reproducible upon reactivation after a washout period.

Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
Zacks Investment Research • Zacks Equity Research • June 24, 2024

Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Top 4 Health Care Stocks That Should Keep You Up At Night
Benzinga • Lisa Levin • September 21, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock...

Why Shares of Orchestra BioMed Jumped Tuesday
The Motley Fool • [email protected] (Jim Halley) • September 19, 2023

The company got approval from the FDA to go ahead with a pivotal study for a hypertension therapy.